Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Enablex To Enter Crowded Urinary Incontinence Market In Early ‘05

Executive Summary

Novartis plans to enter the urinary incontinence market in early 2005 with the launch of its newly approved overactive bladder therapy Enablex

You may also be interested in...



Overactive Bladder Ads Become Frequent; 3 DTC Spots Break In Last 2 Months

Pfizer, Johnson & Johnson and GlaxoSmithKline/ Yamanouchi have each released new direct-to-consumer TV advertisements for their overactive bladder products in the last two months as the sector has become more competitive

Overactive Bladder Ads Become Frequent; 3 DTC Spots Break In Last 2 Months

Pfizer, Johnson & Johnson and GlaxoSmithKline/ Yamanouchi have each released new direct-to-consumer TV advertisements for their overactive bladder products in the last two months as the sector has become more competitive

Pfizer Expects Menstrually-Associated Migraine Claim For Relpax

Pfizer expects Relpax (eletriptan) to be the first triptan to receive a labeling claim for relief of menstrually-associated migraines.

Topics

UsernamePublicRestriction

Register

PS045190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel